Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Jarushka Naidoo, Scott Antonia, Yi‐Long Wu, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 5, pp. 657-663
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
Shun Lu, Terufumi Kato, Xiaorong Dong, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 7, pp. 585-597
Closed Access | Times Cited: 89
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 6, pp. 928-940
Closed Access | Times Cited: 19
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Current and Future Treatment Options in the Management of Stage III NSCLC
Yuchen Li, Rosalyn A. Juergens, Christian Finley, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 11, pp. 1478-1491
Open Access | Times Cited: 20
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
Leilei Wu, Zhenshan Zhang, Menglin Bai, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 19
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Ilaria Attili, Antonio Passaro, Carla Corvaja, et al.
Cancer Treatment Reviews (2023) Vol. 119, pp. 102602-102602
Closed Access | Times Cited: 18
Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges
Jordi Remón, Stephanie P.L. Saw, Francesco Cortiula, et al.
Journal of Thoracic Oncology (2023) Vol. 19, Iss. 2, pp. 199-215
Open Access | Times Cited: 18
New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors
Stephanie P.L. Saw, Xiuning Le, Lizza E.L. Hendriks, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
Yiqing Huang, Joseph J. Zhao, Yu Yang Soon, et al.
Thoracic Cancer (2022) Vol. 13, Iss. 22, pp. 3152-3161
Open Access | Times Cited: 24
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges
Angelica D’Aiello, Brendon M. Stiles, Nitin Ohri, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 3, pp. 197-214
Closed Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis
Luqing Zhao, Zhiting Zhao, Xiaoqi Yan, et al.
International Journal of Clinical Practice (2024) Vol. 2024, pp. 1-10
Open Access | Times Cited: 4
Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer
Chiara Reina, Berina Šabanović, Chiara Lazzari, et al.
Translational research (2024) Vol. 272, pp. 41-53
Closed Access | Times Cited: 4
Cell-Free Circulating Tumor DNA for Non-Invasive Molecular Profiling Among Patients Undergoing Definitive Chemoradiation for Locally Advanced Lung Cancer
Emily S. Lebow, Jordan Eichholz, Lillian Boe, et al.
Advances in Radiation Oncology (2025) Vol. 10, Iss. 4, pp. 101727-101727
Open Access
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”
Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, et al.
Cancer Treatment Reviews (2025) Vol. 135, pp. 102918-102918
Open Access
Recent advances in therapeutic strategies for non-small cell lung cancer
Po‐Lan Su, Naoki Furuya, Atif Asrar, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Traitement standard du cancer bronchique non à petites cellules localement avancé non résécable
Corentin Pasquier, Jonathan Khalifa
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S52-3S63
Closed Access
Next-generation Sequencing Helps to Make the Definite Diagnosis of Adenocarcinoma of Unknown Primary Site: A Case Report
Ling-Jen Hung, Wei-Pang Ho, Chiao‐En Wu
Journal of Cancer Research and Practice (2025) Vol. 12, Iss. 1, pp. 16-19
Open Access
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Jinyong Kim, Sehhoon Park, Bo Mi Ku, et al.
Cancer (2025) Vol. 131, Iss. S1
Closed Access
Stereotactic body radiation therapy in the management of lung neoplasms: is it ready for prime time?
Nicholas Eustace, Arya Amini, Jyoti Malhotra, et al.
Current Opinion in Pulmonary Medicine (2025)
Closed Access
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Ross A. Soo, Filippo de Marinis, Ji‐Youn Han, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 1, pp. 80-84
Open Access | Times Cited: 10
Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review
David McMahon, Ronan Andrew McLaughlin, Jarushka Naidoo
Cancers (2024) Vol. 16, Iss. 3, pp. 527-527
Open Access | Times Cited: 3
Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101)
Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, et al.
Cancer Science (2024) Vol. 115, Iss. 4, pp. 1273-1282
Open Access | Times Cited: 3
Subsequent surgical treatment or maintenance immunotherapy in stage III lung cancer patients achieving a favorable response following neoadjuvant immunotherapy: A matched retrospective cohort study from the surgical perspective
Fuqiang Dai, Cong Chen, Guanyu Zhou, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 10, pp. 830-846
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top